Evidence map›Paper›PMID 36831678›Full record

ArticleCancers2023

Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant

Siyoung Ha, Bi-Dar Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. In Silico Assessment ofJournal of pharmacopuncture · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Siyoung HaDepartment of Pharmaceutical Sciences, University of Maryland Eastern Shore School of Pharmacy and Health Professions, Princess Anne, MD 21853, USA.
Bi-Dar WangDepartment of Pharmaceutical Sciences, University of Maryland Eastern Shore School of Pharmacy and Health Professions, Princess Anne, MD 21853, USA.ORCID 0000-0002-2530-7020
University of Maryland, Baltimore · USUniversity of Maryland Eastern Shore · US

Funding

Aberrant Splice Variants as Potential Precision Biomarkers for Aggressive Prostate Cancers in African American PatientsSC1GM127256 · NIGMS · UNIVERSITY OF MARYLAND EASTERN SHORE · PI WANG, BI-DAR · 2019 to 2022
$1.6M
NIGMS NIH HHS 5SC1GM127256NIGMS NIH HHS SC1 GM127256
6 · The paper itself

Abstract

Targeting PI3Kδ has emerged as a promising therapy for hematologic and non-hematologic malignancies. Previously, we identified an oncogenic splice variant,

Indexed as

aberrant PIK3CD splice variantIdelalisib resistancemolecular dockingprostate cancer disparitiesSRSF2-mediated splicingsynergistic drug therapy

Identifiers

PMID36831678
PMCPMC9954641
OpenAlexW4321377844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.